SEC Company Response from Entero Therapeutics, Inc. (GRDX) (CIK 0001604191) (GRDX) — Aug 9, 2016
Entero Therapeutics, Inc. (GRDX) (CIK 0001604191)
Date: Aug. 9, 2016 · CIK: 0001604191 · Accession: 0001415889-16-006745
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-212511
Letter
Re:
azurrxcorresp_aug92016.htm
August 9, 2016
Securities and Exchange Commission
450 Fifth Street, N.W.
Washington, D.C. 20549
AzurRx BioPharma, Inc.
Registration Statement on Form S-1
File No. 333-212511
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), the undersigned hereby join in the request of AzurRx BioPharma, Inc. that the effective date of the above-captioned Registration Statement be accelerated to 5:00 p.m. on August 11, 2016, or as soon thereafter as practicable.
In connection with the Preliminary Prospectus distribution for the above-captioned issue, the prospective underwriters have confirmed that they are complying with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
The following information with respect to the distribution of the Preliminary Prospectus dated July 29, 2016 is furnished pursuant to Rule 460 of the Rules and Regulations of the Commission under the Securities Act, in connection with the request for acceleration of the effective date of the Registration Statement.
The undersigned have effected approximately the following distribution of copies of the Preliminary Prospectus, dated July 29, 2016, through the date hereof:
Preliminary Prospectus, dated July 29, 2016:
116 copies were distributed to prospective underwriters, institutional investors, dealers and others.
[Remainder of page intentionally left blank]
Very truly yours,
WallachBeth Capital, LLC
Show Raw Text
CORRESP
1
filename1.htm
azurrxcorresp_aug92016.htm
August 9, 2016
Securities and Exchange Commission
450 Fifth Street, N.W.
Washington, D.C. 20549
Re:
AzurRx BioPharma, Inc.
Registration Statement on Form S-1
File No. 333-212511
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), the undersigned hereby join in the request of AzurRx BioPharma, Inc. that the effective date of the above-captioned Registration Statement be accelerated to 5:00 p.m. on August 11, 2016, or as soon thereafter as practicable.
In connection with the Preliminary Prospectus distribution for the above-captioned issue, the prospective underwriters have confirmed that they are complying with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
The following information with respect to the distribution of the Preliminary Prospectus dated July 29, 2016 is furnished pursuant to Rule 460 of the Rules and Regulations of the Commission under the Securities Act, in connection with the request for acceleration of the effective date of the Registration Statement.
The undersigned have effected approximately the following distribution of copies of the Preliminary Prospectus, dated July 29, 2016, through the date hereof:
Preliminary Prospectus, dated July 29, 2016:
116 copies were distributed to prospective underwriters, institutional investors, dealers and others.
[Remainder of page intentionally left blank]
Very truly yours,
WallachBeth Capital, LLC
as Representative of the Several Underwriters
By: /s/ Dan Tapia
Name: Dan Tapia
Title: Chief Compliance Officer
Network 1 Financial Securities, Inc.
as Representative of the Several Underwriters
By: /s/ Jonathan Gazdak
Name: Jonathan Gazdak
Title: Managing Director